Doctors warn of possible rationing on critical childhood cancer drug
Doctors are warning that shortages of a drug used to treat childhood cancer may force them to start rationing the medicine.
The New York Times reported that there is not an adequate substitute for the drug, vincristine, which is used to treat most childhood cancers including leukemias, lymphomas and brain tumors.
{mosads}“This is truly a nightmare situation,” said Dr. Yoram Unguru, a pediatric oncologist at the Herman and Walter Samuelson Children’s Hospital at Sinai in Baltimore, told the Times.
“Vincristine is our water. It’s our bread and butter. I can’t think of a disease in childhood cancer that doesn’t use vincristine,” Unguru added.
He told the newspaper that shortages of the drug could affect kids across the country and force doctors to make difficult decisions.
Pfizer spokeswoman Jessica Smith told the newspaper the company would expedite more shipments of vincristine over the next few weeks to “support three to four times our typical production output,” to compensate for Teva leaving the market.
Teva spokesperson Kelley Dougherty told The Hill in a statement on Tuesday that its discontinuation did not contribute to the shortage.
“Availability of Teva product has not contributed to the shortage that is being experienced today,” Dougherty said.
“Teva evaluated data from 2017 to assess the market need for vincristine. At that time, the market share split was on average 85 percent brand and only 15 percent generic/Teva,” she added. “Based on this information about usage and availability and an annual business assessment, Teva decided to discontinue the product, and alerted FDA of its decision in March 2019.”
Copyright 2023 Nexstar Media Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
